Testosterone booster lawsuits represent one of the largest mass litigation battles in pharmaceutical history, targeting manufacturers of testosterone replacement therapy (TRT) products including AndroGel, Testim, and Axiron over claims that they misrepresented safety risks and caused serious cardiovascular events. Since 2014, thousands of men have sued pharmaceutical companies alleging the products increased their risk of heart attacks, strokes, and blood clots—injuries the manufacturers allegedly failed to adequately warn about or actively concealed. The litigation has resulted in hundreds of millions of dollars in settlements, jury verdicts, and regulatory actions, with the federal multidistrict litigation consolidating nearly 5,000 cases now closed as of March 2025.
These lawsuits emerged after testosterone replacement therapy exploded in popularity during the 2000s and 2010s, marketed aggressively to men experiencing age-related testosterone decline. What the manufacturers did not adequately disclose to patients and doctors, according to court documents and jury findings, was that men using these products faced significantly elevated cardiovascular risks—a fact that major studies later confirmed. The litigation has fundamentally reshaped how pharmaceutical companies market hormone replacement products and has exposed anticompetitive practices used by industry leaders to prevent cheaper generic alternatives from reaching the market.
Table of Contents
- WHAT HEALTH RISKS PROMPTED THE TESTOSTERONE BOOSTER LAWSUITS?
- THE MAJOR SETTLEMENTS AND MULTIMILLION-DOLLAR VERDICTS
- THE FEDERAL MULTIDISTRICT LITIGATION AND CONSOLIDATION
- THE FALSE MARKETING AND FAILURE-TO-WARN CLAIMS
- THE FTC’S ANTICOMPETITIVE CONDUCT FINDINGS
- ELIGIBILITY AND CLAIMS PROCESS
- CURRENT STATUS AND FUTURE LITIGATION LANDSCAPE
- Conclusion
WHAT HEALTH RISKS PROMPTED THE TESTOSTERONE BOOSTER LAWSUITS?
The core allegation driving testosterone replacement therapy litigation is that these products substantially increased the risk of cardiovascular events including heart attack, stroke, and deep vein thrombosis (blood clots) in users. Men taking products like AndroGel and Testim reported experiencing heart attacks at younger ages than typical, sometimes within months or weeks of starting testosterone therapy. The manufacturers—including AbbVie, Endo Pharmaceuticals, and Eli Lilly—faced accusations of knowing about these cardiovascular risks but either downplaying them in marketing materials or failing to warn healthcare providers and patients adequately.
Medical research published during and after the initial litigation surge supported these claims. Studies in the Journal of the American Medical Association and other peer-reviewed publications documented increased cardiovascular event rates among testosterone replacement therapy users, particularly in older men and those with pre-existing heart disease. This created a stark contrast between what manufacturers promoted (testosterone as a safe “anti-aging” solution and treatment for low testosterone) and what the data showed (serious, potentially life-threatening cardiovascular complications). The disconnect between marketing claims and actual safety profiles became the foundation for false advertising and failure-to-warn claims.
THE MAJOR SETTLEMENTS AND MULTIMILLION-DOLLAR VERDICTS
The largest monetary outcomes in testosterone booster litigation stem from AbbVie’s AndroGel product, which dominated the market with over $1 billion in annual sales at its peak. In a significant jury verdict before 2018, a court found AbbVie liable for fraudulent misrepresentation of AndroGel’s benefits and awarded $150 million in punitive damages—a verdict that signaled manufacturers faced real financial exposure if they went to trial. Rather than risk similar outcomes, AbbVie announced a tentative settlement of 4,200 pending AndroGel lawsuits in September 2018, though the specific settlement amount was not publicly disclosed. Competing manufacturers also faced substantial liability.
Endo Pharmaceuticals, maker of Testim (a competing testosterone gel), announced a $200 million settlement in June 2018 to resolve approximately 1,300 lawsuits. Eli Lilly & Co. settled around 400 federal lawsuits in December 2017 accusing the company of misrepresenting its testosterone replacement products. Even supplement manufacturers faced consequences—makers of Testofen, a fenugreek-based testosterone supplement, settled for $7 million in 2018. These settlements, combined with the jury verdict against AbbVie, totaled well over $350 million in direct compensation, not including regulatory penalties and consumer relief orders.
THE FEDERAL MULTIDISTRICT LITIGATION AND CONSOLIDATION
In June 2014, federal courts created Multidistrict Litigation 2545 (MDL-2545) to consolidate testosterone replacement therapy lawsuits filed across the country, a procedural mechanism designed to efficiently manage complex, multi-party litigation. Overseen by U.S. District Judge Matthew F. Kennelly in the Northern District of Illinois, the MDL consolidated nearly 5,000 cases involving men who alleged testosterone replacement products caused cardiovascular injuries.
This centralized approach allowed the court to handle discovery (evidence gathering), establish consistent legal standards, and pressure manufacturers to negotiate global settlements rather than face thousands of individual trials. The MDL-2545 operated for over a decade, moving through discovery phases, establishing bellwether trials (representative cases designed to gauge jury sentiment), and facilitating settlement negotiations. As of March 2025, the MDL has officially closed with no remaining federal cases pending. This closure represents the end of a significant chapter in pharmaceutical litigation, though it does not mean every injured plaintiff settled—some cases were dismissed, some settled individually, and some claimants may have foregone legal action. The consolidation process, while efficient from a court administration perspective, also limited individual plaintiffs’ ability to pursue highly customized claims and potentially affected settlement values for some claimants.
THE FALSE MARKETING AND FAILURE-TO-WARN CLAIMS
At the heart of testosterone booster litigation are legal theories of false marketing and failure to warn—claims that manufacturers either made affirmative false statements about safety or failed to adequately communicate known risks to medical professionals and patients. Marketing materials for AndroGel often emphasized benefits like increased energy, improved sexual function, and general vitality while treating cardiovascular risks as rare or theoretical. Internal company documents obtained during litigation discovery showed that manufacturers possessed safety data contradicting their marketing claims, yet continued to promote the products aggressively to maximize sales.
The failure-to-warn claims are particularly significant because testosterone replacement therapy is a prescription product; doctors prescribe it based on the information provided in package inserts and marketing materials. If manufacturers knew—or should have known—that cardiovascular risks were substantially higher than disclosed, they had a legal duty to communicate this information clearly to the prescribing physicians. Plaintiffs’ lawyers documented instances where marketing materials minimized cardiovascular warnings or placed them in small print while highlighting benefits prominently, a layout that discouraged careful reading. This asymmetry between risk communication and benefit promotion formed the basis for punitive damages awards, since jurors could infer the manufacturers’ conduct was deliberate and reckless.
THE FTC’S ANTICOMPETITIVE CONDUCT FINDINGS
Beyond product liability litigation, testosterone replacement therapy manufacturers faced scrutiny from the Federal Trade Commission for anticompetitive behavior. In a landmark decision, the FTC found in June 2018 that AbbVie had used sham litigation as a weapon to illegally maintain its AndroGel monopoly and block generic competitors from entering the market. A U.S.
District Court awarded $448 million in consumer relief based on this finding—money designed to compensate consumers harmed by inflated prices resulting from the company’s anticompetitive conduct. The FTC’s case against AbbVie revealed that the company filed questionable patent litigation against generic manufacturers not to protect legitimate intellectual property, but rather to slow generic entry and preserve AndroGel’s market dominance and premium pricing. When the Third Circuit Court of Appeals reviewed the case in September 2020, it affirmed the FTC’s liability findings and reinstated the reverse payment claim, confirming that using litigation as an anticompetitive tool violated federal law. This regulatory action demonstrates that testosterone booster litigation extended beyond individual injury claims to encompass broader competition and consumer protection issues.
ELIGIBILITY AND CLAIMS PROCESS
Eligibility for testosterone replacement therapy settlements generally required proof that a plaintiff used one of the named testosterone products (AndroGel, Testim, Axiron, or similar products) and subsequently suffered a qualifying cardiovascular event such as heart attack, stroke, or blood clot. Most settlement agreements established claim deadlines, and claimants typically needed to provide medical records documenting both the use of the testosterone product and the subsequent injury, along with expert medical testimony linking the injury to testosterone use. Settlement amounts varied based on the severity of injury, age of the claimant, pre-existing medical conditions, and whether the claimant was deemed partially contributory (e.g., smokers or those with obesity might receive reduced awards).
For the large settlements like those involving AndroGel and Testim, claimants were required to submit claims within specified windows—often 12 to 24 months after a settlement was announced. Claims that were timely submitted and met medical eligibility criteria were typically paid from settlement trusts established by manufacturers. However, not all injured men pursued settlements; some preferred individual litigation if they believed their injuries warranted higher compensation, while others were unaware of available settlements or missed filing deadlines. Consulting with a personal injury attorney experienced in pharmaceutical litigation was often essential to navigating claim requirements and maximizing recovery.
CURRENT STATUS AND FUTURE LITIGATION LANDSCAPE
With MDL-2545 closed and major settlements finalized, the testosterone replacement therapy litigation landscape has shifted significantly. Men who did not settle their claims during the MDL period or afterward face a more challenging legal environment—they would need to file individual lawsuits under applicable statutes of limitations, which vary by state and may have already expired for injuries occurring in the early or mid-2010s. Some states have repose periods that cut off liability entirely after a certain period, even if the plaintiff did not discover the injury immediately.
However, new litigation may emerge if additional health risks from testosterone replacement therapy are identified, or if new product formulations with inadequate warning labels reach the market. The closure of the federal MDL does not prevent state court litigation or future class actions. Additionally, as testosterone replacement therapy remains medically prescribed, ongoing regulatory scrutiny from the FDA regarding labeling and marketing claims continues. Physicians and patients should remain aware that testosterone replacement therapy carries documented cardiovascular risks, particularly for older men or those with existing heart disease, and medical decisions should reflect current safety information rather than outdated marketing claims.
Conclusion
Testosterone booster lawsuits represent a major victory for consumer protection and pharmaceutical accountability, resulting in over $350 million in direct settlements and an additional $448 million in consumer relief from FTC anticompetitive findings. The litigation demonstrated that large pharmaceutical manufacturers cannot escape liability for false marketing and failure-to-warn claims when internal evidence contradicts promotional statements, and that courts will award substantial punitive damages to punish deliberate deception. The closure of MDL-2545 in March 2025 marks the end of the centralized federal litigation phase, though individual state-level claims and regulatory scrutiny continue.
If you believe you suffered a cardiovascular injury after using testosterone replacement therapy products, check whether applicable statutes of limitations in your state permit filing a claim, and consult with a qualified personal injury attorney immediately. The window for joining group settlements has largely closed, but individual litigation may still be available depending on your state’s laws and the date of your injury. Medical evidence documenting your testosterone use and subsequent injury will be essential to any claim.